A new clinical trial is exploring SA53-OS, an MDM2 inhibitor, for people with advanced solid tumors, including #dedifferentiated #liposarcoma (#DDLPS). Learn more about this study, who may be eligible, and how the treatment is given.
clinicaltrials.gov/study/NCT065...
#ClinicalTrials #MDM2